JPMorgan Chase & Co. Sells 271,731 Shares of Enhabit, Inc. $EHAB
JPMorgan Chase & Co. decreased its stake in Enhabit, Inc. (NYSE:EHAB) by 48.2% in the third quarter, selling 271,731 shares and retaining 291,823 shares valued at $2.34 million. Enhabit reported Q3 EPS of $0.14 and revenue of $270.4 million, with a current market cap of $708.81 million. Analyst consensus rates Enhabit as a "Hold" with an average target price of $13.57.
Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?
This article analyzes whether Enhabit, Inc. (EHAB) stock is outperforming its medical peers in the current year. It likely compares EHAB's stock performance against sector averages or other relevant medical companies to assess its market position.
Enhabit (EHAB) deal: $13.80 cash takeover backed by Kinderhook ($688M equity)
Enhabit, Inc. is being acquired by Anchor Parent, LLC, an affiliate of Kinderhook Industries, for $13.80 per share in cash, representing a 33.8% premium to its 60-day volume-weighted average price through February 20, 2026. Kinderhook-affiliated funds are committing $688 million in equity to fund the $690.4 million transaction, which is unanimously recommended by Enhabit's Board of Directors. The deal will result in Enhabit becoming a private company, delisting its stock from the NYSE, and ceasing SEC filings.
Tudor Investment Corp ET AL Lowers Stock Position in Enhabit, Inc. $EHAB
Tudor Investment Corp ET AL reduced its stake in Enhabit, Inc. by 24.5% during the third quarter, while several other large institutional investors increased their positions, indicating mixed sentiment. Enhabit (NYSE:EHAB) reported quarterly earnings in line with estimates and revenue close to expectations, despite having a negative net margin. The stock currently holds a consensus "Hold" rating from analysts with an average target price of $13.57.
Enhabit, Inc. (NYSE:EHAB) Receives Consensus Recommendation of "Hold" from Analysts
Enhabit, Inc. (NYSE:EHAB) has received a consensus "Hold" rating from nine analysts, with an average 12-month price target of $13.57. Recent insider activity shows EVP Julie Diane Jolley sold 2,793 shares, reducing her stake by 1.96%. The company reported Q4 EPS of $0.14, meeting estimates, and revenues of $270.4 million, with a current market capitalization of approximately $692.6 million.
Enhabit (NYSE:EHAB) - Stock Analysis
This Simply Wall St stock analysis of Enhabit (NYSE:EHAB) highlights its current market valuation at US$692.9m and its stock price of US$13.66. The report suggests the stock is undervalued, with earnings forecast to grow by 26.59% per year, driven by aging demographics and increasing demand for home health and hospice services. While showing strong historical returns against its industry and the broader market, the analysis notes significant insider selling as a risk.
Are EWCZ, KORE, EHAB Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sales of European Wax Center, Inc. (EWCZ), KORE Group Holdings, Inc. (KORE), and Enhabit, Inc. (EHAB). The firm is concerned that these transactions may not offer fair deals to ordinary shareholders, as insiders might receive disproportionate financial benefits or the terms could restrict superior offers. Shareholders of these companies are encouraged to contact Halper Sadeh LLC to discuss their rights and options.
Vanguard disaggregates holdings after realignment (EHAB)
The Vanguard Group has filed an amendment (SCHEDULE 13G/A) for Enhabit Inc., reporting zero beneficial ownership of common stock due to an internal realignment effective January 12, 2026. This change leads to disaggregated reporting by certain Vanguard subsidiaries, following SEC Release No. 34-39538. The filing, signed by Ashley Grim, confirms no single other person's interest exceeds 5%.
Enhabit Q1 2025 Results: Admissions Growth and Payer Mix Shift - News and Statistics
Enhabit reported its first quarter 2025 results, highlighting significant admissions growth and a positive shift in payer mix. The company saw an 8.1% sequential increase in admissions and a 7.4% year-over-year rise in non-Medicare admissions, driven by payer innovation contracts. This strategic shift contributed to a 7.6% yearly improvement in non-Medicare revenue per visit.
Enhabit, Inc. (NYSE:EHAB) Short Interest Update
Enhabit, Inc. (NYSE:EHAB) saw a significant 20.6% drop in short interest in February, reducing the shares sold short to 2.5% of the company's outstanding shares with a low days-to-cover ratio of 0.3 days. Analysts maintain a consensus "Hold" rating for EHAB, with an average price target of $13.57. The company recently reported Q4 EPS of $0.14, meeting estimates, on revenues of $270.4 million, and disclosed an insider stock sale by an EVP.
8 Knots Management LLC Has $33.79 Million Position in Enhabit, Inc. $EHAB
8 Knots Management LLC has significantly increased its stake in Enhabit, Inc. (NYSE:EHAB) by 9.5%, now holding 4,218,846 shares valued at $33.79 million, making it their 11th largest holding. Analysts currently rate EHAB as a "Hold" with an average price target of $13.57, despite some recent upgrades to "Buy." The company recently reported quarterly EPS of $0.14, meeting estimates, and has a market capitalization of approximately $690.5 million.
Enhabit (NYSE: EHAB) CFO logs 18,370-share stock grant in amended Form 4
Enhabit, Inc.'s CFO, Ryan Solomon, reported an amended insider transaction via Form 4/A, indicating he received a grant of 18,370 shares of common stock at $13.61 per share. This amendment corrects a clerical error from a previous filing. Following this grant, Solomon directly owns 193,911 common shares of Enhabit.
Enhabit EVP Jolley sells $76k in common stock
Julie Diane Jolley, EVP of Home Health Operations at Enhabit, Inc. (NYSE: EHAB), sold 5,586 shares of common stock for a total of $76,137 on March 9 and 10, 2026. This sale occurred as EHAB trades near its 52-week high, with the stock categorized as overvalued by InvestingPro. The company is also set to be acquired by Kinderhook Industries for $13.80 per share, a deal that has led analysts to adjust ratings and price targets.
Enhabit (EHAB) EVP Jolley sells 5,586 common shares in open market
Enhabit, Inc.'s EVP of Home Health Operations, Julie Diane Jolley, sold a total of 5,586 common shares in the open market across two transactions on March 9 and 10, 2026. Each transaction involved 2,793 shares sold at $13.63 per share. Following these sales, Ms. Jolley directly holds 137,130 Enhabit common shares.
Enhabit (EHAB) EVP Kalvaitis records 6,724-share stock grant in Form 4/A
Enhabit, Inc. Executive Vice President of Hospice Operations, Jeanne Louise Kalvaitis, reported an amended Form 4 to correct a clerical error regarding a stock award. The filing indicates she acquired 6,724 shares of common stock as a grant at $13.61 per share. Following this correction, Kalvaitis directly holds 61,875 common shares.
Enhabit’s (EHAB) Collin McQuiddy, chief accounting officer, sells $19,094 in stock
Enhabit's Chief Accounting Officer, Collin McQuiddy, sold 1,403 shares of company stock for $19,094, with the sale occurring as the stock is near its 52-week high after a strong 59% return. InvestingPro analysis suggests the stock is currently overvalued. This comes amidst news of Enhabit's acquisition by Kinderhook Industries for $13.80 per share, leading to several analyst downgrades and price target adjustments to align with the acquisition price.
Enhabit (EHAB) CHRO receives 10,287-share stock grant in amendment
Enhabit, Inc.'s Chief Human Resources Officer, Tanya Renee Marion, received a stock grant of 10,287 shares on March 6, 2026, at $13.61 per share. This amendment to her insider trading activity corrects a clerical error that led to the omission of this award in the original filing. Following this grant, her direct holdings increased to 103,339 shares, with an additional 1,712 shares held indirectly by her spouse.
Enhabit (EHAB) CAO sells 1,403 shares in open-market stock sale
Enhabit, Inc.'s Chief Accounting Officer, Collin McQuiddy, sold 1,403 shares of common stock in an open-market transaction on March 11, 2026, at $13.61 per share. Following this sale, McQuiddy directly holds 3,991 shares of Enhabit common stock. This insider activity was reported in a Form 4 SEC filing, indicating a neutral impact on the stock with negative sentiment.
Insider Sell Alert: Julie Jolley Sells Shares of Enhabit Inc (EHAB)
Julie Jolley, Executive Vice President of Home Health Operations at Enhabit Inc, sold 5,586 shares of the company on March 10, 2026, and now holds 137,130 shares. This transaction is part of a pattern of insider sells for Enhabit Inc, with one buy and two sells over the past year. Shares were trading at $13.63, and GuruFocus indicates the stock is significantly overvalued with a price-to-GF-Value ratio of 1.47.
Enhabit (NYSE:EHAB) EVP Sells $38,068.59 in Stock
Enhabit (NYSE:EHAB) EVP Julie Diane Jolley sold 2,793 shares of the company's stock on March 9th for a total of $38,068.59, reducing her stake by 1.96%. The sale occurred at an average price of $13.63 per share. Analysts currently rate Enhabit as a "Hold" with a consensus price target of $13.57.
Enhabit’s (EHAB) Collin McQuiddy, chief accounting officer, sells $19,094 in stock
Enhabit, Inc.'s Chief Accounting Officer, Collin McQuiddy, sold 1,403 shares of common stock for $19,094, with the stock trading near its 52-week high and appearing overvalued according to InvestingPro. This comes as Enhabit recently announced an acquisition by Kinderhook Industries for $1.1 billion, leading to several analyst downgrades and synchronized price targets of $13.80 per share.
[Form 4] Enhabit, Inc. Insider Trading Activity
Collin McQuiddy, Chief Accounting Officer of Enhabit, Inc. (EHAB), reported a tax-related disposition of 592 common shares at $13.61 per share. These shares were withheld to cover tax withholding obligations upon the vesting of restricted stock. After this transaction, McQuiddy directly owns 5,394 common shares.
Enhabit (NYSE:EHAB) CAO Sells $19,094.83 in Stock
Enhabit (NYSE:EHAB) CAO Collin Mcquiddy sold 1,403 shares of the company's stock for $19,094.83, reducing his position by 26.01%. Following the sale, he now directly owns 3,991 shares valued at approximately $54,317.51. The company's shares are currently trading at $13.62, and it holds a consensus "Hold" rating from analysts with a target price of $13.57.
Segall Bryant & Hamill LLC Takes Position in Enhabit, Inc. $EHAB
Segall Bryant & Hamill LLC has initiated a new position in Enhabit, Inc. (NYSE: EHAB), purchasing 240,415 shares valued at approximately $1.93 million. This investment represents about 0.48% of Enhabit at the end of the last quarter. Enhabit, a national provider of home-based healthcare services, reported quarterly EPS of $0.14 on revenue of $270.4 million and has a consensus "Hold" rating from analysts with an average price target of $13.57.
Enhabit (EHAB) Q4 Loss Rekindles Debate Around Turnaround And Profitability Narratives
Enhabit (EHAB) reported a Q4 2025 revenue of US$270.4 million and a basic EPS loss of US$0.76, continuing its trend of negative net income. While the company has shown a reduction in its trailing twelve-month loss and modest revenue growth, its profitability narrative remains a subject of debate among investors. The article highlights both bullish arguments, focusing on narrowing losses and anticipated future positive earnings, and bearish concerns regarding slower revenue growth, reimbursement pressures, and the sensitivity of financial results.
TD Cowen Reaffirms "Hold" Rating for Enhabit (NYSE:EHAB)
TD Cowen has reaffirmed its "Hold" rating for Enhabit (NYSE:EHAB) with a $13.80 price target, implying a 1.40% upside. Enhabit recently reported quarterly earnings of $0.14 per share, matching estimates, and revenue of $270.4 million, which was nearly in line with expectations. The company, a national provider of home-based healthcare services, currently has a consensus "Hold" rating from analysts on MarketBeat with an average target price of $13.57.
Enhabit Reaches ‘Pivotal’ Growth Inflection Point
Enhabit Inc. is anticipating a year of accelerated growth in 2026, driven by increasing hospice and home health revenues and its recent acquisition by Kinderhook Industries LLC. The company achieved significant milestones in 2025, including year-over-year increases in patient census, revenue, and adjusted EBITDA, positioning it for further expansion and investment. The $1.1 billion acquisition by Kinderhook Industries is expected to close in Q2 2026 and aims to fuel long-term investments in workforce development and clinical excellence while enabling "smart, durable" growth.
Enhabit Q4 2025 Financial Results: Net Loss, $270.4M Revenue | Home Health & Hospice - News and Statistics
Enhabit Inc. reported a net loss of $38.7 million, or 76 cents per share, for the fourth quarter of 2025, with adjusted earnings of 14 cents per share. The company generated $270.4 million in revenue during the quarter. For the full fiscal year 2025, Enhabit posted a loss of $4.6 million, or 9 cents per share, on total revenue of $1.06 billion.
Shareholder Investigation Launched by Kaskela Law Firm into Fairness of Enhabit, Inc. (NYSE: EHAB) Buyout Price; EHAB Investors Encouraged to Contact the Firm
Kaskela Law LLC has initiated an investigation into the proposed buyout of Enhabit, Inc. (NYSE: EHAB) by Kinderhook Industries for $13.80 per share in cash. The firm questions whether this buyout price adequately values Enhabit's shares and whether the company's leadership fulfilled their fiduciary duties. Enhabit shareholders who believe the offer is too low are encouraged to contact Kaskela Law for information on their legal rights.
Enhabit 2025 10-K: $1,060.0M Revenue, $(0.09) EPS
Enhabit reported full-year 2025 consolidated net service revenue of $1,060.0 million, a 2.4% increase from 2024, attributed mainly to robust Hospice growth while Home Health modestly declined. The company significantly narrowed its net loss to $(2.6) million from $(154.0) million in 2024, and diluted basic loss per share improved to $(0.09) from $(3.11). Operational efficiencies and strategic growth initiatives, including de novo openings and acquisitions, contributed to these improved financial results.
Shareholder Investigation Launched by Kaskela Law Firm into Fairness of Enhabit, Inc. (NYSE: EHAB) Buyout Price; EHAB Investors Encouraged to Contact the Firm
Kaskela Law LLC has initiated an investigation into the proposed buyout of Enhabit, Inc. (NYSE: EHAB) to determine if the $13.80 per share offer undervalues the company. The firm encourages Enhabit shareholders who believe the buyout price is too low to contact them, as they prepare to assess whether the company's officers and directors breached their fiduciary duties. This comes after Enhabit announced on February 23, 2026, its agreement to be acquired by Kinderhook Industries.
Enhabit: Fourth Quarter Financial Overview
Enhabit Inc. reported a Q4 net loss of $38.7 million, or $0.76 per share, with adjusted earnings of $0.14 per share and $270.4 million in revenue. For the full year, the company had a total loss of $4.6 million, or $0.09 per share, on annual revenue of $1.06 billion. Enhabit specializes in home health and hospice care.
Enhabit: Q4 Earnings Snapshot
Enhabit Inc. (EHAB) reported a fourth-quarter loss of $38.7 million, equating to 76 cents per share. Excluding certain costs, adjusted earnings were 14 cents per share on revenue of $270.4 million. For the full year, the home health and hospice services provider posted a loss of $4.6 million, or 9 cents per share, with total revenue of $1.06 billion.
Enhabit: Q4 Earnings Snapshot
Enhabit Inc. (EHAB) reported a fourth-quarter loss of $38.7 million, or 76 cents per share, with adjusted earnings of 14 cents per share. The home health and hospice services provider posted quarterly revenue of $270.4 million. For the full year, Enhabit recorded a loss of $4.6 million on $1.06 billion in revenue.
Enhabit: Q4 Earnings Snapshot
Enhabit Inc. (EHAB) reported a fourth-quarter loss of $38.7 million, or 76 cents per share, though adjusted earnings were 14 cents per share. The home health and hospice services provider posted revenue of $270.4 million for the quarter and $1.06 billion for the full year, with an annual loss of $4.6 million. This financial data was generated using information from Zacks Investment Research.
Enhabit Amends Credit Agreement, Secures New Loan Facilities
Enhabit, Inc. (EHAB) refinanced its debt on February 26, 2026, by securing new $475 million credit facilities including a $315 million term loan A and a $160 million revolving credit facility, both maturing in five years. These facilities introduce new covenants and leverage tests that will influence the company's future capital flexibility. The proceeds will be used to refinance previous debt, cover fees, and support general corporate purposes, with the facilities being secured by company assets and subject to financial maintenance tests.
Enhabit Secures $475 Million Five-Year Credit Facilities Led by Wells Fargo
Enhabit has secured $475 million in new five-year credit facilities, led by Wells Fargo Bank, to refinance existing debt and for general corporate purposes. The facilities include a $315 million Term Loan A and a $160 million revolving credit facility, priced at SOFR plus a margin of 2.25%. The agreement, signed on February 26, 2026, also sets financial covenants, including a maximum total net leverage ratio and a minimum fixed charge coverage ratio.
Enhabit, Inc. (NYSE:EHAB) Receives Consensus Rating of "Hold" from Brokerages
Nine research firms have given Enhabit, Inc. (NYSE:EHAB) a consensus "Hold" rating, with an average 12-month price target of $13.3143. Several analysts recently adjusted their ratings and price targets, including upgrades and downgrades. The company's stock opened at $13.60 and has a market capitalization of $688.30 million, with institutional investors showing increased interest in its shares.
Enhabit Home Health & Hospice Announces Date of 2025 Fourth Quarter Earnings Call
Enhabit, Inc. announced it will release its fourth-quarter and fiscal year 2025 financial results on March 4, 2026. The company will also host a conference call and webcast on March 5, 2026, at 9 a.m. EST for investors and interested parties to discuss the results. Details for joining the call and accessing the webcast replay are provided.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—EHAB, CECO, LSF, and SKTL
Class Action Attorney Juan Monteverde, with Monteverde & Associates PC, is investigating the mergers of Enhabit Inc. (EHAB) with Kinderhook Industries, LLC, CECO Environmental Corp. (CECO) with Thermon Group Holdings, Inc., Laird Superfoods, Inc. (LSF) with Navitas LLC, and SunOpta Inc. (STKL) with Pegasus BidCo B.V. The firm, headquartered in the Empire State Building, specializes in recovering funds for shareholders and encourages concerned shareholders to contact them for more information.
Enhabit, Inc. (EHAB) Stock Analysis: Navigating Challenges with Strategic Home Health and Hospice Services
Enhabit, Inc. (EHAB) specializes in home health and hospice services within the U.S. healthcare sector. The company maintains a strong operational foundation with a market cap of approximately $689.39 million, focusing on essential health services despite financial headwinds like negative EPS and ROE. Analysts hold a cautious outlook, with a consensus target price suggesting it's nearing full valuation, though its vital services and potential for operational improvements offer long-term opportunities for investors.
Enhabit (EHAB) Chief Accounting Officer McQuiddy to exit; CFO Solomon adds role
Enhabit, Inc. announced that its Senior Vice President and Chief Accounting Officer, Collin McQuiddy, will resign effective March 27, 2026, to pursue another career opportunity. He will assist with the transition until his departure. Chief Financial Officer Ryan Solomon will assume the role of principal accounting officer temporarily without additional compensation, and the company stated there were no disagreements leading to McQuiddy's resignation.
Enhabit (EHAB) Stock Price, News & Analysis
Enhabit Inc. (EHAB) is a national provider of home-based healthcare services. The company's stock shows a "Hold" consensus rating from analysts, with recent news indicating a potential acquisition deal with Kinderhook for $1.1 billion. EHAB's shares have increased by 47.4% year-to-date and the company recently reported earnings that beat analyst estimates.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Enhabit Inc. (NYSE: EHAB)
Monteverde & Associates PC ("the M&A Class Action Firm") has announced an investigation into Enhabit Inc. (NYSE: EHAB) concerning its proposed sale to Kinderhook Industries, LLC. The firm is examining whether the cash offer of $13.80 per share for Enhabit shareholders is a fair deal. Attorney Juan Monteverde, known for recovering millions for shareholders, encourages concerned investors to contact the firm for a free consultation.
Enhabit (EHAB) Expected to Announce Earnings on Wednesday
Enhabit (NYSE:EHAB) is scheduled to release its Q4 2025 earnings after market close on Wednesday, March 4th. Analysts forecast earnings of $0.14 per share and revenue of $270.5590 million. The company's stock has recently seen significant movement due to an agreement to be acquired by Kinderhook Industries for $13.80 per share in an all-cash deal.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Enhabit, Inc. (EHAB)
Brodsky & Smith is investigating potential claims against Enhabit, Inc.'s Board of Directors regarding the company's sale to Kinderhook Industries, LLC for $13.80 per share, totaling $1.1 billion. The investigation will assess whether the Board failed to conduct a fair process and ensure the deal consideration provides fair value to shareholders. Shareholders of Enhabit are invited to contact the law office with any questions regarding the legal ramifications.
What Enhabit’s $1.1B Acquisition Means for the Hospice Landscape
Enhabit Inc. is being acquired by private equity firm Kinderhook Industries LLC for $1.1 billion, a deal signaling a growing interest in hospice assets within the private equity sector. The acquisition is expected to provide Enhabit with additional resources and expertise for long-term investments without the short-term pressures of public markets, while not significantly altering day-to-day operations or team structure. This transaction highlights a trend of increasing private equity investment in the hospice space, driven by the value proposition of these services in reducing costs and improving quality of care.
Demystifying Enhabit: Insights From 6 Analyst Reviews
Six analysts have provided mixed ratings for Enhabit (NYSE: EHAB) over the last three months, with an average 12-month price target of $13.23, representing a 28.45% increase from the previous average. The company shows strong financial performance in net margin, ROE, and ROA, but its revenue growth lags industry peers and it has a high debt-to-equity ratio. The article details recent analyst actions, including rating changes and price target adjustments, and provides an overview of Enhabit's market capitalization, financial health, and services.
Home Health And Hospice Provider Enhabit To Go Private In $1.1B Deal
Kinderhook Industries is set to acquire Enhabit, a home health and hospice provider, in an all-cash transaction valued at approximately $1.1 billion. Enhabit shareholders will receive $13.80 per share, a 24% premium to its recent closing price. This deal will take Enhabit private, delisting it from the NYSE, and reflects a broader trend of private equity investment in the home-based care sector.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Enhabit, Inc. (EHAB)
Brodsky & Smith is investigating potential claims against the Board of Directors of Enhabit, Inc. (EHAB) concerning its sale to Kinderhook Industries, LLC for $13.80 per share. The investigation centers on whether the Enhabit Board breached its fiduciary duties to shareholders by failing to conduct a fair process and ensure the deal provides fair value. Shareholders affected by this transaction are encouraged to contact Brodsky & Smith for legal consultation.
